About SEA-CD40

SEA-CD40 utilizes our novel sugar-engineered antibody (SEA) technology to produce a non-fucosylated antibody targeting CD40. It builds on our extensive experience targeting CD40, an immune-activating receptor capable of driving an antitumor response. Preclinical data show that SEA-CD40 may stimulate a patient's own immune system to fight their cancer. A non-ADC program developed by our scientists, SEA-CD40 represents an alternative approach to empowering antibodies that is complementary to our ADC technology.


SEA-CD40 is in a phase 1 trial in metastatic or unresectable solid tumors and hematologic malignancies.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave